A Point Of Harmony On Avandia
This article was originally published in Pharmaceutical Approvals Monthly
What will the REMS redesign process mean for the day-to-day decision-making at FDA? The latest data on use of REMS surely provides a clue: FDA will invoke the new authorities a bit more judiciously than might have been the case a year ago.
You may also be interested in...
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.
FDA has approved over 50 new molecular entities in a year for the second time – a truly remarkable job amid a global pandemic. But will 2021 be a tougher year?